Key Market Insights
 A number of players currently claim to have the required capabilities to offer contract manufacturing / conjugation services for antibody drug conjugates, worldwide
 A significant portion of agreements signed in recent years are focused on product development and manufacturing; multiple large-sized firms have also signed agreements pertaining to ADCs
 In order to meet the rising demand for ADC therapeutics, CMOs have made elaborate investments to expand their capacities, primarily for clinical purposes; this trend is most pronounced in the US and Switzerland
 More than 80 ADC therapeutic developers were evaluated as strategic partners to forge manufacturing alliances with contract service providers, to further enhance their capabilities within the domain
 In 2035, close to 50% of the demand for ADC therapeutics is likely to be generated in North America; further, a sizeable proportion of the current demand is generated by commercialized therapeutics
 In the past few years, several new clinical trials have been registered; around 85% of such studies are evaluating candidates in early stages of development
 The installed global contract manufacturing capacity for ADCs is well distributed across different geographies; large players account for 90% of the total capacity
 The installed capacity is sufficient to meet the current overall annual demand; however, as the demand rises, CMOs will be required to invest in installing incremental capacity
 With over 70% of the ADC manufacturing operations currently being outsourced, we expect the market to grow at an annualized rate of over 12% over the next decade
 The anticipated opportunity is expected to be segregated across a variety of linkers and antibodies; it is also likely to be well-distributed across the key geographical regions


Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Components of Antibody Drug Conjugates (ADCs)
3.3. ADC Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.6. Future Perspective

4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
4.3. List of Antibody Contract Manufacturing Service Providers
4.4. List of HPAPI / Cytotoxic Payload Contract Manufacturing Service Providers
4.5. List of Biologics Fill / Finish Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. MabPlex
5.2.1. Company Overview
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Development and Future Outlook
5.3. AbbVie Contract Manufacturing
5.4. Lonza
5.5. Catalent Pharma Solutions
5.6. Goodwin Biotechnology
5.8. Millipore Sigma
5.9. Abzena
5.10. CARBOGEN AMCIS
5.11. WuXi Biologics
5.12. Cerbios-Pharma
5.13. Formosa Laboratories
5.14. Creative Biolabs
5.15. Novasep
5.16. Sterling Pharma Solutions

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. ADC Contract Manufacturing Service Providers: Company Competitiveness Analysis

7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturing Service Providers: Recent Expansions


8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations


9. MAKE VERSUS BUY DECISION MAKING
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Concluding Remarks

10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. ADC Development Value Chain
10.3. Cost Distribution Across the Value Chain

11. ADC MANUFACTURING: CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. ADC Manufacturing: Global Installed Capacity

12. ADC THERAPEUTICS: MARKET OVERVIEW
12.1. Chapter Overview
12.2. List of ADC Therapeutics
12.3. Antibody Drug Conjugates: List of Therapy Developers

13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. First Generation ADC Technologies
13.3. Second Generation ADC Technologies
13.4. Third Generation ADC Technologies
13.5. Other Emerging ADC Technologies
13.6. Evolutionary Analysis

14. CLINICAL TRIALS ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Therapeutics: Clinical Trial Analysis
14.4. ADC Therapeutics: Analysis by Antibody Isotope and Geography
14.5. ADC Therapeutics: Analysis by Type of Payload and Geography
14.6. ADC Therapeutics: Analysis by Type of Linker and Geography

15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Key Potential Strategic Partners for ADC Therapeutics Developers

16. ADC THERAPEUTICS: DEMAND ANALYSIS
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. ADC Therapeutics: Overall Annual Demand
16.4. ADC Therapeutics: Demand and Supply Analysis

17. REGIONAL CAPABILITY ASSESSMENT ANALYSIS
17.1. Chapter Overview
17.2. Assumptions and Key Parameters
17.3. Regional Capability Assessment in North America
17.4. Regional Capability Assessment in Europe
17.5. Regional Capability Assessment in Asia-Pacific

18. ATTRACTIVENESS COMPETETIVENESS MATRIX
18.1. Chapter Overview
18.2. AC Matrix: Overview
18.3. Analytical Methodology
18.4. AC Matrix: ADC Contract Manufacturing Scenario for Type of Service(s) Offered, 2022-2028
18.5. AC Matrix: ADC Contract Manufacturing Scenario for Type of Service(s) Offered, 2029-2035
18.6. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographies, 2022-2028
18.7. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographies, 2029-2035

19. MARKET SIZING AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Forecast Methodology
19.3. Global ADC Therapeutics Market, 2022-2035
19.4. Input Data and Key Assumptions

19.5. Global ADC Contract Manufacturing Market, 2022-2035
19.6. ADC Contract Manufacturing Market for Commercial Products, 2022-2035
19.7. ADC Contract Manufacturing Market for Clinical Products, 2022-2035


20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.3. Weaknesses
20.4. Opportunities
20.5. Threats
20.6. Comparison of SWOT Factors

21. CONCLUDING REMARKS

22. INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. BSP Pharmaceuticals
22.3. Oxford BioTherapeutics
22.4. Abzena
22.5. Syndivia
22.6. Cerbios-Pharma
22.7. NBE-Therapeutics
22.8. Eisai
22.9. Synaffix
22.10. Pierre Fabre
22.11. Goodwin Biotechnology
22.12. Cerbios-Pharma
22.13. Catalent Pharma Solutions
22.14. Lonza
22.15. Piramal Pharma Solutions
22.16. Ajinomoto Bio-Pharma Services
22.17. Interview Transcript: Anonymous (Director, Business Development, Leading CMO)
22.18. Interview Transcript: Anonymous (Chief Executive Officer, Leading CMO)

23. APPENDIX I: TABULATED DATA

24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html

Learn from experts: do you know about these emerging industry trends?
Agricultural Biologicals: An Answer to a Sustainable Future
Berkus Method of Start-up Valuation to Evaluate Start-ups Engaged in Digital Twins Domain
Watch for These Anti Aging Companies Progressing Longevity Research Through Cellular Reprogramming

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]